Paddling furiously, to go backwards!
A popular AIM company covered here is struggling to make a return on substantial revenue – it could be an interesting recovery play, but significant and regularly recurring exceptional costs are also a concern to us. There was better news elsewhere, with upgrades for a software group and another important approval for a highly rated provider of infection prevention products. (Premium)
Tristel receives another approval
Tristel (AIM: TSTL), the manufacturer of infection prevention products utilising its proprietary chlorine dioxide technology, has announced that Health Canada has approved Tristel ULT as a Class II Medical Device for endocavity ultrasound probes and skin surface transducers. The timing of this regulatory approval comes well ahead of the Company's original aim for gaining approval and allows commercial launch during FY 2024.
The Health Canada approval, alongside the earlier…
Continue reading our content…
- Unlimited access to our market-beating portfolios
- In-depth coverage of many of the world’s great companies
- Unique insights from our top research team
- Company and markets insights
- Sponsored content
- Podcasts
Previous article Next article
